OR WAIT null SECS
- About Us
- Advertise
- Contact Us
- Editorial Info
- Editorial Contacts
- Editorial Advisory Board
- Do Not Sell My Personal Information
- Privacy Policy
- Terms and Conditions
© 2024 MJH Life Sciences™ and Pharmaceutical Technology. All rights reserved.
CMIC group Announces Integration of Chinese Subsidiaries
CPS will be integrated into CB, who will proceed as the operating company while CMIC group continues to expand its business in China.
CMIC group, a contract research organization (CRO), announced that it reorganized its clinical CRO business in China and integrated its subsidiaries CMIC (Beijing) Co., Ltd. (CB) and CMIC (Beijing) Pharmaceutical Services Co., Ltd. (CPS) on April 1, 2020.
According to a company press release, CPS will be integrated into CB, who will proceed as the operating company while CMIC group continues to expand its business in China. Additionally, the company hopes the merger will advance its business strategies and operations execution while solidifying its clinical CRO services in China under one combined unit.
“Through this merger, CMIC group is able to leverage combined know-how and accumulated experiences enabling the company to provide higher quality, better efficiency, and seamless service solutions in China,” said Pey Ni Chan, general manager of CB, in the press release “We are committed to be a trusted partner for our clients not only offering Chinese patients access to new treatments, but also to be a reliable navigator to Chinese companies looking for business expansions into Japan and other growing markets in the Asia-Pacific, as well as in the United States.”
